Process for the preparation of 17.beta.-hydroxy-20-alkoxypregnane-21-oic
acid derivatives
    3.
    发明授权
    Process for the preparation of 17.beta.-hydroxy-20-alkoxypregnane-21-oic acid derivatives 失效
    制备17 {62-羟基-20-烷氧基孕烷-21-酸酸衍生物的方法

    公开(公告)号:US4155923A

    公开(公告)日:1979-05-22

    申请号:US873444

    申请日:1978-01-30

    IPC分类号: C07J1/00 C07J13/00 C07J7/00

    摘要: A process for the preparation of 17.beta.-hydroxy-20-alkoxypregnane-21-oic acid derivatives of the formula ##STR1## WHEREIN R.sub.1 is methyl or ethyl;R.sub.2 is hydrogen or methyl, either being in the .alpha.-or .beta.-position;R.sub.3 is lower alkyl of 1-4 carbon atoms;R.sub.4 is alkyl of 1-8 carbon atoms or benzyl; andSt is the residue of a steroid ABC ring system;Comprises reacting (a) a 17-oxo compound of the formula ##STR2## WHEREIN R.sub.1 and R.sub.2 are as defined above andSt* is said steroid ABC ring system residue, St, in a form which is chemically compatible with said reaction;With (b) an enolate ion of an alkoxyacetic acid alkyl ester of the formula ##STR3## wherein R.sub.3 and R.sub.4 are as defined above.

    摘要翻译: 制备式Ia的17β-羟基-20-烷氧基孕烷-21-酸酸衍生物的方法,其中R1是甲基或乙基; R2是氢或甲基,或者是α位或β-位; R3是1-4个碳原子的低级烷基; R4是1-8个碳原子的烷基或苄基; St是类固醇ABC环系统的残基; 包含反应(A)制剂的17-OXO化合物,其中R1和R2如上所定义,St *是所述类固醇ABC环系统残基St,以与所述反应化学相容的形式; 具有(B)式(A)的化合物,其中R 3和R 4如上所定义的烷氧基酸酯。

    Process for the preparation of trans-deca hydronaphthalene derivatives
    4.
    发明授权
    Process for the preparation of trans-deca hydronaphthalene derivatives 失效
    反十氢化萘衍生物的制备方法

    公开(公告)号:US4077996A

    公开(公告)日:1978-03-07

    申请号:US676805

    申请日:1976-04-14

    CPC分类号: C07F7/1856 C07D317/50

    摘要: A process for the preparation of trans-decahydronaphthalene compounds of Formula I ##STR1## wherein X is lower alkyl, --(CH.sub.2).sub.3 --Z--R.sub.2, ##STR2## --(CH.sub.2).sub.3 COOR.sub.4, or --(CH.sub.2).sub.3 CN; Y and Z are ketalized carbonyl or free, esterified, or etherified hydroxymethylene;U is halogen;R.sub.1, r.sub.2, and R.sub.3 are lower alkyl; andR.sub.4 is alkyl;Wherein an octahydronaphthalene compound of Formula II ##STR3## is converted, in the presence of bases, by reaction of a trialkyl chlorosilane of the formula(R.sub.5).sub.3 Si--Clwherein the R.sub.5 each are lower alkyl group, to a hexahydronaphthalene compound of the formula ##STR4## The hexahydronaphthalene compound is hydrogenated, in an inert solvent with hydrogen in the presence of a platinum-, palladium-, or rhodium-containing hydrogenation catalyst, to an octahydronaphthalene compound of the formula ##STR5## and a vinyl ketone of the formulaXCOCH.dbd.CH.sub.2is added to the thus-obtained octahydronaphthalene compound in an inert solvent in the presence of a Lewis acid.

    摘要翻译: 制备式I的反十氢萘化合物的方法,其中X是低级烷基, - (CH 2)3 -Z-R 2, - (CH 2)3 COOR 4或 - (CH 2)3 C 3; Y和Z是缩酮化羰基或游离的,酯化的或醚化的羟基亚甲基; U是卤素; R1,R2和R3是低级烷基; 和R4是烷基; 在碱的存在下,通过式(R5)3Si-Cl的三烷基氯硅烷与各自为低级烷基的R 5反应得到式II的六氢萘化合物,其中式II的甲氧基二苯甲酮化合物转化为 式VI化合物在惰性溶剂中,在含有铂,钯或铑的氢化催化剂的存在下,用氢气将其氢化成式为“八氢”的八氢化合物和式 在路易斯酸存在下,在惰性溶剂中将式XCOCH = CH 2加入到如此获得的八氢萘化合物中。

    Process for the preparation of 13.beta.-alkyl-4-gonene-3,17-diones
    5.
    发明授权
    Process for the preparation of 13.beta.-alkyl-4-gonene-3,17-diones 失效
    制备13 {62-烷基-4-锑烯-3,17-二酮的方法

    公开(公告)号:US4024166A

    公开(公告)日:1977-05-17

    申请号:US621384

    申请日:1975-10-10

    摘要: Novel process for the preparation of 13.beta.-alkyl-4-gonene-3,17-diones of the formula ##STR1## wherein R.sub.1 is methyl or ethyl, consists of REACTING A 7A.beta.-ALKYL,5,6,7,7A-TETRAHYDROINDANE-1,5-DIONE WITH FORMALDEHYDE AND AN ARYLSULFINIC ACID OR AN ADDUCT OF FORMALDEHYDE AND ARYLSULFINIC ACID TO PRODUCE A TETRAHYDROINDANE DERIVATIVE;Hydrogenating the tetrahydroindane derivative with hydrogen in the presence of a palladium-, platinum-, or rhodium-containing hydrogenation catalyst to produce a perhydroindane derivative;Condensing the perhydroindane derivative in the presence of a proton-accepting agent with a 7,7-alkylenedioxy-3-oxooctanoic acid ester;Treating the product obtained with a strong aqueous base and then heating the product in an inert solvent to produce a 4,5-secosteroid;Hydrogenating the 4,5-secosteroid in the presence of a palladium-, platinum-, rhodium-, or nickel-containing hydrogenation catalyst; andHydrolyzing and cyclizing the hydrogenated 4,5-secosteroid by treatment with a strong acid.

    摘要翻译: 用于制备式“IMAGE”的13β-烷基-4-单宁-3,17-二酮的新方法,其中R 1是甲基或乙基,由反应A7Aβ-烷基,5,6,7,7a- 四氢呋喃-1,5-二酮与甲醛和氨基磺酸或甲醛和芳香酸的添加以生产四氢衍生物衍生物; 在含有氢氧化钯,或含氢氧化铑的氢化催化剂存在下氢化四氢呋喃衍生物生成四氢呋喃衍生物; 在具有7,7-亚甲基氧化亚硝酸酯酸酯的接受原料的情况下,冷凝该衍生物衍生物; 处理用强碱性基质获得的产品,然后加入产品中的产品用于生产4,5代谢物; 在含有钯,铑,铑,或含镍的氢化催化剂存在下氢化4,5-二氧化硫; 并通过用强酸处理氢化和循环氢化的4,5代谢物。

    D-Homo-19-norsteroids
    8.
    发明授权
    D-Homo-19-norsteroids 失效
    D-Homo-19-诺贝星

    公开(公告)号:US4057561A

    公开(公告)日:1977-11-08

    申请号:US770433

    申请日:1977-02-22

    CPC分类号: C07J63/008

    摘要: D-homosteroids of the formula ##STR1## WHEREIN R.sup.3.alpha. is hydrogen, R.sup.3.beta. is hydroxy, lower alkanoyloxy or aroyloxy and R.sup.3.alpha. and R.sup.3.beta. taken together are oxo; R.sup.17a.alpha. is hydrogen, lower alkyl, ethynyl, vinyl, allyl, methallyl, propadienyl, 1-propynyl, butadiynyl or chloroethynyl; R.sup.17a.beta. is hydrogen, alkanoyl, aroyl, lower alkyl, cycloalkyl-lower-alkyl, benzyl, furfuryl or tetrahydropyranyl; R.sup.18 is hydrogen or methyl and the dotted line in the C-ring denotes an additional carbon to carbon bond in the 11,12-position andProcesses for the preparation thereof are disclosed.The D-homosteroids of the present invention are useful as ovulation inhibitors and androgenic/anabolic agents.

    摘要翻译: 式中的β-均质甾族化合物,其中R3a是氢,R3β是羟基,低级烷酰氧基或芳酰氧基,R3a和R3β一起是氧代; R17a是氢,低级烷基,乙炔基,乙烯基,烯丙基,甲代烯丙基,丙炔基,1-丙炔基,丁二炔基或氯乙炔基; R17aβ是氢,烷酰基,芳酰基,低级烷基,环烷基 - 低级 - 烷基,苄基,糠基或四氢吡喃基; R18是氢或甲基,C环中的虚线表示11,12位中的另外的碳 - 碳键,并且其制备方法被公开。

    19,11 .beta.-bridged steroids, their manufacture and pharmaceutical
preparations containing them
    10.
    发明授权
    19,11 .beta.-bridged steroids, their manufacture and pharmaceutical preparations containing them 失效
    19,11(BETA) - 混合型STEROIDS,其制造和含有它们的药物制剂

    公开(公告)号:US5095129A

    公开(公告)日:1992-03-10

    申请号:US283632

    申请日:1988-12-09

    摘要: New 19,11.beta.-bridged steroids of the general formula I ##STR1## where R.sup.1 stands for a methyl or ethyl radical,R.sup.2 for a hydrogen or chlorine atom or a C.sub.1 -C.sub.4 -alkyl radical,B and G, which are the same or different, respectively for a hydrogen atom, a C.sub.1 -C.sub.4 -alkyl radical or, together, for a second bond between the carbon atoms 6 and 7,B and R.sup.2 together for a methylene or an ethylene group,Z for the radical of a pentagonal or hexagonal ring, which is possibly substituted and possibly unsaturated,V stands for a possibly substituted carbocyclic or heterocyclic aryl radical,the ring A for ##STR2## M and N together meaning a second bond or M a hydrogen atom and N a hydroxy group,X means an oxygen atom, two hydrogen atoms or a hydroxyimino grouping N.about.OH,R.sup.3 and D, which are the same or different, respectively a hydrogen atom, a nitrile radical or a C.sub.1 -C.sub.4 -alkyl radical or, together, a methylene or ethylene group,E a hydrogen atom or a C.sub.1 -C.sub.4 -alkyl radical,D and E together meaning a second bond between carbon atoms 1 and 2 or together a methylene group ##STR3## with R.sup.11 in the meaning of a hydrogen atom or a C.sub.1 -C.sub.8 -alkyl radical,are described as well as their pharmaceutically tolerated addition salts with acids. The new compounds possess valuable pharmacological properties.

    摘要翻译: 新的19,11个β-桥连类固醇,其通式为Ⅰ(Ⅰ),其中R1代表甲基或乙基,R2代表氢或氯原子或C1-C4烷基,B和G,其中 分别对于氢原子,C 1 -C 4 - 烷基或碳原子6和7之间的第二个键,B和R 2一起为亚甲基或亚乙基,Z为相同或不同的 可能被取代且可能不饱和的五角或六方环的基团V代表可能被取代的碳环或杂环芳基,A,A,M和N一起表示第二个键或M是氢原子 和N是羟基,X表示氧原子,两个氢原子或羟基亚氨基基团N分别OH,R3和D分别相同或不同,分别为氢原子,腈基或C1-C4烷基 或者一起是亚甲基或亚乙基,E是氢原子或C 1 -C 4烷基,D和E togeth 呃意指碳原子1和2之间的第二个键或一起与氢原子或C 1 -C 8 - 烷基的含义中的R 11一起形成的亚甲基基团b)或者c),以及 它们与酸的药学上耐受的加成盐。 新化合物具有宝贵的药理性质。